Larimar Therapeutics, Inc.
Clinical trials sponsored by Larimar Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Hope for Friedreich's ataxia: new drug trial aims to slow disease progression Results expected Jan 2027 (estimated)
-
Hope for Friedreich's ataxia: new drug trial aims to slow disease progression
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of an experimental drug called CTI-1601 for people with Friedreich's ataxia, a rare genetic disease that affects movement and heart function. It includes about 85 adolescents and adults who have or have not taken the dr…
Phase 2 • Sponsor: Larimar Therapeutics, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a missing protein be replaced to slow Friedreich's ataxia?
Disease control Recruiting nowThis phase 3 trial is testing whether a weekly injection of nomlabofusp can improve balance and slow the progression of Friedreich's ataxia, a genetic condition that damages the nervous system. The study includes about 150 adults and children with the disease, who will receive ei…
Phase 3 • Sponsor: Larimar Therapeutics, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC